Violich Capital Management Inc. Trims Holdings in Kenvue Inc. (NYSE:KVUE)

Violich Capital Management Inc. decreased its holdings in Kenvue Inc. (NYSE:KVUE) by 10.9% in the 4th quarter, Holdings Channel reports. The firm owned 36,114 shares of the company’s stock after selling 4,415 shares during the period. Violich Capital Management Inc.’s holdings in Kenvue were worth $771,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently bought and sold shares of KVUE. FMR LLC increased its stake in Kenvue by 2.3% in the 3rd quarter. FMR LLC now owns 137,915,493 shares of the company’s stock valued at $3,189,985,000 after buying an additional 3,075,019 shares during the period. State Street Corp increased its stake in Kenvue by 16.8% in the 3rd quarter. State Street Corp now owns 127,213,940 shares of the company’s stock valued at $2,942,458,000 after buying an additional 18,283,473 shares during the period. Massachusetts Financial Services Co. MA increased its stake in Kenvue by 8.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 86,979,341 shares of the company’s stock valued at $2,011,832,000 after buying an additional 7,115,374 shares during the period. Geode Capital Management LLC increased its stake in Kenvue by 0.9% in the 3rd quarter. Geode Capital Management LLC now owns 44,677,077 shares of the company’s stock valued at $1,029,810,000 after buying an additional 399,846 shares during the period. Finally, Harris Associates L P increased its stake in Kenvue by 7.5% in the 3rd quarter. Harris Associates L P now owns 31,459,511 shares of the company’s stock valued at $727,658,000 after buying an additional 2,186,114 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Stock Up 2.1 %

KVUE opened at $20.60 on Tuesday. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The firm has a market cap of $39.49 billion, a P/E ratio of 38.86, a PEG ratio of 2.16 and a beta of 1.45. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $24.46. The business’s fifty day simple moving average is $21.54 and its 200 day simple moving average is $22.00.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, equities research analysts anticipate that Kenvue Inc. will post 1.05 EPS for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be paid a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a yield of 3.98%. The ex-dividend date is Wednesday, February 12th. Kenvue’s payout ratio is 154.72%.

Wall Street Analyst Weigh In

KVUE has been the topic of several recent research reports. Royal Bank of Canada reissued a “sector perform” rating and issued a $24.00 price objective on shares of Kenvue in a research note on Monday, February 3rd. Deutsche Bank Aktiengesellschaft cut shares of Kenvue from a “buy” rating to a “hold” rating and lowered their price target for the stock from $25.00 to $24.00 in a research note on Thursday, December 12th. Citigroup lowered their price target on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 15th. Piper Sandler raised shares of Kenvue from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $21.00 to $26.00 in a research note on Monday, January 6th. Finally, UBS Group lowered their price target on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a research note on Friday. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the stock. According to MarketBeat, Kenvue presently has a consensus rating of “Hold” and an average target price of $23.00.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.